{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:55:04Z","timestamp":1791219304393,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113407","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T17:15:56Z","timestamp":1729185356000},"page":"113407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"P2","title":["Saroglitazar ameliorates 5- Fluorouracil-induced hepatorenal damage in rats"],"prefix":"10.1016","volume":"143","author":[{"given":"Alhomedy M.","family":"Alharbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda E.","family":"Kafl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania R.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3283-9471","authenticated-orcid":false,"given":"Ghada M.","family":"Suddek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113407_b0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.sajb.2019.08.038","article-title":"Moringa Oleifera Seed Oil Modulates Redox Imbalance and iNOS\/NF-\u03baB\/Caspase-3 Signaling Pathway to Exert Antioxidant, Anti-Inflammatory and Antiapoptotic Mechanisms against Anticancer Drug 5-Fluorouracil-Induced Nephrotoxicity in Rats\u201d","author":"Famurewa","year":"2019","journal-title":"South African Journal of Botany"},{"issue":"1","key":"10.1016\/j.intimp.2024.113407_b0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/0960327115573597","article-title":"Taurine ameliorates 5-flourouracil-induced intestinal mucositis, hepatorenal and reproductive organ damage in Wistar rats: A biochemical and histological study","volume":"35","author":"Al-Asmari","year":"2016","journal-title":"Human & Experimental Toxicology."},{"issue":"2","key":"10.1016\/j.intimp.2024.113407_b0130","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1634\/theoncologist.6-2-162","article-title":"Hepatotoxicity of chemotherapy","volume":"6","author":"King","year":"2001","journal-title":"The Oncologist"},{"key":"10.1016\/j.intimp.2024.113407_b0220","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/DMSO.S49592","article-title":"Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence","volume":"8","author":"Sosale","year":"2015","journal-title":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy."},{"key":"10.1016\/j.intimp.2024.113407_b0175","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1932296813518680","article-title":"A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)","volume":"8","author":"Pai","year":"2014","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.intimp.2024.113407_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117729","article-title":"Saroglitazar attenuates renal fibrosis induced by unilateral ureteral obstruction via inhibiting TGF-\u03b2\/Smad signaling pathway","volume":"253","author":"Makled","year":"2020","journal-title":"Life Sciences"},{"key":"10.1016\/j.intimp.2024.113407_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109688","article-title":"Saroglitazar, a dual PPAR-\u03b1\/\u03b3 agonist, alleviates LPS-induced hepatic and renal injury in rats","volume":"115","author":"Francis","year":"2023","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.intimp.2024.113407_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116774","article-title":"Saroglitazar mitigated NASH-associated hepatic injury in dexamethasone-treated rats via modulating autophagy, apoptosis, and necroptosis","volume":"482","author":"Amer","year":"2024","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"3","key":"10.1016\/j.intimp.2024.113407_b0065","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1471-4159.2012.07688.x","article-title":"Characterization of cerebral glucose dynamics in vivo with a four-state conformational model of transport at the blood-brain barrier","volume":"121","author":"Duarte","year":"2012","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.intimp.2024.113407_b0135","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.intimp.2024.113407_b0245","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1073\/pnas.0409786102","article-title":"A Mendelian locus on chromosome 16 determines susceptibility to doxorubicin nephropathy in the mouse","volume":"102","author":"Zheng","year":"2005","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.intimp.2024.113407_b0050","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2020.00730","article-title":"Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases","volume":"11","author":"Decara","year":"2020","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"10.1016\/j.intimp.2024.113407_b0095","first-page":"1809","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology (Baltimore","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Md.)"},{"issue":"12","key":"10.1016\/j.intimp.2024.113407_b0160","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00210-019-01703-5","article-title":"The dual PPAR-\u03b1\/\u03b3 agonist saroglitazar ameliorates thioacetamide-induced liver fibrosis in rats through regulating leptin","volume":"392","author":"Makled","year":"2019","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"issue":"6","key":"10.1016\/j.intimp.2024.113407_b0070","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.dsx.2020.08.039","article-title":"Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis","volume":"14","author":"Dutta","year":"2020","journal-title":"Diabetes & Metabolic Syndrome"},{"issue":"4","key":"10.1016\/j.intimp.2024.113407_b0100","first-page":"404","article-title":"The protective effects of naringin against 5-fluorouracil-induced hepatotoxicity and nephrotoxicity in rats","volume":"21","author":"Gelen","year":"2018","journal-title":"Iranian Journal of Basic Medical Sciences"},{"issue":"5","key":"10.1016\/j.intimp.2024.113407_b0145","doi-asserted-by":"crossref","first-page":"F618","DOI":"10.1152\/ajprenal.00309.2013","article-title":"Proximal tubule PPAR\u03b1 attenuates renal fibrosis and inflammation caused by unilateral ureteral obstruction","volume":"305","author":"Li","year":"2013","journal-title":"American Journal of Physiology. Renal Physiology"},{"issue":"2","key":"10.1016\/j.intimp.2024.113407_b0240","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/hep.22657","article-title":"Alanine aminotransferase isoenzymes: molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity","volume":"49","author":"Yang","year":"2009","journal-title":"Hepatology (baltimore, Md.)"},{"key":"10.1016\/j.intimp.2024.113407_b0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/B978-0-12-803620-4.00017-7","article-title":"Biomarkers in Nonclinical Drug Development","author":"Aulbach","year":"2017","journal-title":"A Comprehensive Guide to Toxicology in Nonclinical Drug Development"},{"issue":"7","key":"10.1016\/j.intimp.2024.113407_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102174","article-title":"Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis","volume":"47","author":"Bandyopadhyay","year":"2023","journal-title":"Clinics and Research in Hepatology and Gastroenterology"},{"issue":"3","key":"10.1016\/j.intimp.2024.113407_b0185","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/jalm\/jfac137","article-title":"LDH and the MELD-LDH in Severe Acute Liver Injury and Acute Liver Failure: Preliminary Confirmation of a Novel Prognostic Score for Risk Stratification","volume":"8","author":"Price","year":"2023","journal-title":"The Journal of Applied Laboratory Medicine"},{"key":"10.1016\/j.intimp.2024.113407_b0165","series-title":"Veterinary Laboratory Medicine: Interpretation and Diagnosis","first-page":"169","article-title":"Hepatobiliary and skeletal muscle enzymes and liver function tests","author":"Meyer","year":"2004"},{"key":"10.1016\/j.intimp.2024.113407_b0250","doi-asserted-by":"crossref","first-page":"12671","DOI":"10.1073\/pnas.231140698","article-title":"Mechanism of indinavir-induced hyperbilirubinemia","volume":"98","author":"Zucker","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.intimp.2024.113407_b0230","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1016\/j.intimp.2024.113407_b0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40360-021-00524-8","article-title":"Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis","volume":"22","author":"Akbari","year":"2021","journal-title":"BMC Pharmacology & Toxicology"},{"issue":"45","key":"10.1016\/j.intimp.2024.113407_b0055","doi-asserted-by":"crossref","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","article-title":"Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1","volume":"274","author":"Delerive","year":"1999","journal-title":"J Biol Chem."},{"issue":"5","key":"10.1016\/j.intimp.2024.113407_b0210","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.28000","article-title":"Stimulation of nuclear receptor PPAR-\u03b3 limits NF-kB-dependent inflammation in mouse cystic fibrosis biliary epithelium","volume":"62","author":"Scirpo","year":"2015","journal-title":"Hepatology."},{"issue":"49","key":"10.1016\/j.intimp.2024.113407_b0180","doi-asserted-by":"crossref","first-page":"32833","DOI":"10.1074\/jbc.273.49.32833","article-title":"Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging","volume":"273","author":"Poynter","year":"1998","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.intimp.2024.113407_b0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11596-020-2146-8","article-title":"Activating PPAR\u03b3 Increases NQO1 and \u03b3-GCS Expression via Nrf2 in Thrombin-activated Microglia","volume":"40","author":"Hang","year":"2020","journal-title":"Curr Med Sci."},{"key":"10.1016\/j.intimp.2024.113407_b0030","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000026","article-title":"Discovering NF-kappaB","volume":"1","author":"Baltimore","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.intimp.2024.113407_b0200","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.arr.2007.09.002","article-title":"Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging","volume":"7","author":"Salminen","year":"2008","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.intimp.2024.113407_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119921","article-title":"Ferulic acid: A review of its pharmacology, pharmacokinetics and derivatives","volume":"284","author":"Li","year":"2021","journal-title":"Life Sciences"},{"issue":"2","key":"10.1016\/j.intimp.2024.113407_b0005","first-page":"241","article-title":"Comparison of the anti-inflammatory and antilipidemic activity of diosmin and saroglitazar in a model of nonalcoholic fatty liver induced by a high-fat diet in Wistar rats","volume":"27","author":"Afarin","year":"2024","journal-title":"Iranian Journal of Basic Medical Sciences"},{"key":"10.1016\/j.intimp.2024.113407_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2024.110084","article-title":"Modulation of keap-1\/Nrf2\/HO-1 and NF-\u0138b\/caspase-3 signaling pathways by dihydromyricetin ameliorates sodium valproate-induced liver injury","volume":"758","author":"Emad","year":"2024","journal-title":"Arch Biochem Biophys."},{"key":"10.1016\/j.intimp.2024.113407_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154791","article-title":"Modulation of 5-fluorouracil activation of toll-like\/MyD88\/NF-\u03baB\/MAPK pathway by Saccharomyces boulardii CNCM I-745 probiotic","volume":"125","author":"Justino","year":"2020","journal-title":"Cytokine."},{"key":"10.1016\/j.intimp.2024.113407_b0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-Mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113407_b0140","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR \u03b1\/\u03b3 Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Scientific Reports"},{"issue":"6","key":"10.1016\/j.intimp.2024.113407_b0060","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic basis for interleukin-1 in disease","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood."},{"key":"10.1016\/j.intimp.2024.113407_b0205","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/apha.12764","article-title":"Biomarkers in acute kidney injury\u2013pathophysiological basis and clinical performance","volume":"219","author":"Schrezenmeier","year":"2017","journal-title":"Acta Physiol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113407_b0190","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cell.2004.07.002","article-title":"Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis","volume":"118","author":"Rakoff-Nahoum","year":"2004","journal-title":"Cell."},{"issue":"9","key":"10.1016\/j.intimp.2024.113407_b0120","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1017\/S0007114513004248","article-title":"Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice","volume":"111","author":"Justino","year":"2014","journal-title":"Br J Nutr."},{"issue":"5","key":"10.1016\/j.intimp.2024.113407_b0195","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1042\/BST0340833","article-title":"The role of scaffold proteins in MEK\/ERK signalling","volume":"34","author":"Sacks","year":"2006","journal-title":"Biochemical Society Transactions."},{"issue":"1","key":"10.1016\/j.intimp.2024.113407_b0235","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1152\/physrev.1999.79.1.143","article-title":"Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human","volume":"79","author":"Widmann","year":"1999","journal-title":"Physiological Reviews."},{"key":"10.1016\/j.intimp.2024.113407_b0045","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/463617","article-title":"The role of MAPK in drug-induced kidney injury","volume":"2012","author":"Cassidy","year":"2012","journal-title":"Journal of Signal Transduction"},{"issue":"1","key":"10.1016\/j.intimp.2024.113407_b0215","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12871-024-02641-3","article-title":"Remimazolam protects the liver from ischemia-reperfusion injury by inhibiting the MAPK\/ERK pathway","volume":"24","author":"Shi","year":"2024","journal-title":"BMC Anesthesiol."},{"key":"10.1016\/j.intimp.2024.113407_b0085","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1080\/15384101.2015.1004937","article-title":"Neuronal cell cycle: the neuron itself and its circumstances. ABBV","volume":"14","author":"Frade","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.intimp.2024.113407_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-71531-8","article-title":"Activated ROCK\/Akt\/eNOS and ET-1\/ERK pathways in 5-fluorouracil-induced cardiotoxicity: modulation by simvastatin","volume":"10","author":"Muhammad","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.intimp.2024.113407_b0110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1101\/gad.13.1.76","article-title":"Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain","volume":"13","author":"Itoh","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.intimp.2024.113407_b0125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.46.120604.141046","article-title":"Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway","volume":"47","author":"Kensler","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.intimp.2024.113407_b0225","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0065-2571(02)00038-9","article-title":"Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis","volume":"43","author":"Talalay","year":"2003","journal-title":"Adv. Enzyme Regul."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924019295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924019295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:32:09Z","timestamp":1736303529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924019295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":50,"alternative-id":["S1567576924019295"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113407","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Saroglitazar ameliorates 5- Fluorouracil-induced hepatorenal damage in rats","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113407"}}